Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu... (atients with seizure disorders Vimpat(R)...)

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

Date:12/8/2008

atients with seizure disorders, Vimpat(R) should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat(R) should be discontinued.

AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat(R) should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

The most common adverse reactions occurring in >10 percent of Vimpat(R)-treated patients, and greater than placebo, were diplopia, headache, dizziness, and nausea.

The FDA has recommended Vimpat(R) as a schedule C-V controlled substance. Scheduling is expected to be finalized in the first quarter of 2009.

Please go to http://www.fda.gov/cder/foi/label/2008/022253lbl.pdf for approved prescribing information.

    Further information
    Andrea Levin
    Public Relations Manager
    T 770.970.8352
    M 404.483.7329
    Andrea.levin@ucb-group.com

    Eimear O'Brien,
    Global CNS Communications Manager, UCB Group
    T +32.2.559.9271
    Eimear.OBrien@ucb-group.com

About UCB

UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on NYSE Euronext (symbol: UCB). Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. F
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers

Post Your Comments:

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu...(atients with seizure disorders Vimpat(R)...)